非酒精性脂肪性肝病合并肥胖患者减重手术后的心血管结局与死亡率
该研究基于TriNetX平台的大型人群回顾性队列,纳入2005年1月1日至2021年12月31日期间接受减重手术的BMI≥35且无肝硬化的非酒精性脂肪性肝病成人,按1:1倾向性匹配非手术对照。减重手术组新发心力衰竭风险(HR 0.60,95%CI 0.51-0.70)、复合心血管事件(HR 0.53,95%CI 0.44-0.65)、复合脑血管病(HR 0.59,95%CI 0.51-0.69)、冠状动脉介入或手术(HR 0.47,95%CI 0.35-0.63)及全因死亡(HR 0.56,95%CI 0.42-0.74)均显著低于非手术组。上述结局在随访1、3、5、7年时保持一致。提示减重手术可能与该人群主要不良心血管事件和死亡风险降低相关。
要点
- 非酒精性脂肪性肝病合并肥胖(BMI≥35、无肝硬化)患者接受减重手术后,新发心力衰竭风险显著低于非手术组(HR 0.60,95%CI 0.51-0.70)。
- 减重手术组复合心血管事件(不稳定型心绞痛、心肌梗死或血运重建)风险显著低于非手术组(HR 0.53,95%CI 0.44-0.65)。
- 减重手术组复合脑血管病风险显著低于非手术组(HR 0.59,95%CI 0.51-0.69)。
- 减重手术组冠状动脉介入或手术风险显著低于非手术组(HR 0.47,95%CI 0.35-0.63),全因死亡风险亦显著更低(HR 0.56,95%CI 0.42-0.74)。
- 上述结局在随访1、3、5、7年时保持一致。
适用人群与场景
- 成人,BMI≥35,非酒精性脂肪性肝病且无肝硬化,于2005年1月1日至2021年12月31日期间接受减重手术者(减重手术组)或未接受手术者(非手术组)。
诊断标准与关键阈值
- 非酒精性脂肪性肝病且无肝硬化,BMI≥35。
处置流程与药物剂量
- 减重手术对比非手术治疗。
研究设计与关键结果
- 研究类型:大型人群回顾性队列,数据来自TriNetX平台;纳入152394例符合条件的成人,其中4693例接受减重手术;4687例减重手术患者(平均[SD]年龄44.8[11.6]岁;3822例[81.5%]女性)与4687例非手术个体(平均[SD]年龄44.7[13.2]岁;3883例[82.8%]女性)按年龄、人口学、合并症和药物进行1:1倾向性匹配。
- 主要终点:减重手术组新发心力衰竭风险显著低于非手术组(HR 0.60,95%CI 0.51-0.70);复合心血管事件风险显著低于非手术组(HR 0.53,95%CI 0.44-0.65);复合脑血管病风险显著低于非手术组(HR 0.59,95%CI 0.51-0.69);冠状动脉介入或手术风险显著低于非手术组(HR 0.47,95%CI 0.35-0.63)。
- 全因死亡:减重手术组显著低于非手术组(HR 0.56,95%CI 0.42-0.74)。
- 上述结局在随访1、3、5、7年时保持一致。
证据类型、等级与局限
- 证据类型:大型人群回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论提示,在非酒精性脂肪性肝病合并肥胖患者中,减重手术与主要不良心血管事件及全因死亡风险降低显著相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Bariatric surgery (BS) is associated with significantly reduced incidence of cardiovascular diseases and mortality in patients with obesity. However, whether BS can decrease major adverse cardiovascular events in patients with nonalcoholic fatty liver disease (NAFLD) remains poorly understood.
OBJECTIVE: To investigate the association of BS with the incidence of adverse cardiovascular events and all-cause mortality in patients with NAFLD and obesity.
DESIGN, SETTING, AND PARTICIPANTS: This was a large, population-based, retrospective cohort using data from the TriNetX platform. Adult patients with a body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) of 35 or greater and NAFLD (without cirrhosis) who underwent BS between January 1, 2005, and December 31, 2021, were included. Patients in the BS group were matched with patients who did not undergo surgery (non-BS group) according to age, demographics, comorbidities, and medication by using 1:1 propensity matching. Patient follow-up ended on August 31, 2022, and data were analyzed in September 2022.
EXPOSURES: Bariatric surgery vs nonsurgical care.
MAIN OUTCOMES AND MEASURES: The primary outcomes were defined as the first incidence of new-onset heart failure (HF), composite cardiovascular events (unstable angina, myocardial infarction, or revascularization, including percutaneous coronary intervention or coronary artery bypass graft), composite cerebrovascular disease (ischemic or hemorrhagic stroke, cerebral infarction, transient ischemic attack, carotid intervention, or surgery), and a composite of coronary artery procedures or surgeries (coronary stenting, percutaneous coronary intervention, or coronary artery bypass). Cox proportional hazards models were used to estimate hazard ratios (HRs).
RESULTS: Of 152 394 eligible adults, 4693 individuals underwent BS; 4687 patients who underwent BS (mean [SD] age, 44.8 [11.6] years; 3822 [81.5%] female) were matched with 4687 individuals (mean [SD] age, 44.7 [13.2] years; 3883 [82.8%] years) who did not undergo BS. The BS group had significantly lower risk of new-onset of HF (HR, 0.60; 95% CI, 0.51-0.70), cardiovascular events (HR, 0.53; 95% CI, 0.44-0.65), cerebrovascular events (HR, 0.59; 95% CI, 0.51-0.69), and coronary artery interventions (HR, 0.47; 95% CI, 0.35-0.63) compared with the non-BS group. Similarly, all-cause mortality was substantially lower in the BS group (HR, 0.56; 95% CI, 0.42-0.74). These outcomes were consistent at follow-up duration of 1, 3, 5, and 7 years.
CONCLUSIONS AND RELEVANCE: These findings suggest that BS was significantly associated with lower risk of major adverse cardiovascular events and all-cause mortality in patients with NAFLD and obesity.
参考来源
- Krishnan A, Hadi Y, Alqahtani SA, et al. Cardiovascular Outcomes and Mortality After Bariatric Surgery in Patients With Nonalcoholic Fatty Liver Disease and Obesity. JAMA Netw Open. 2023. PMID: 37027156. doi:10.1001/jamanetworkopen.2023.7188
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。